%PDF-1.4
%
46 0 obj
<>
endobj
43 0 obj
<>
endobj
95 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-08T11:48:56Z
2024-03-28T01:50:03-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T01:50:03-07:00
application/pdf
Heather
200367.february
uuid:bcb2acdc-1dd1-11b2-0a00-ce0927fd5800
uuid:bcb2acde-1dd1-11b2-0a00-6a0000000000
endstream
endobj
32 0 obj
<>
endobj
33 0 obj
<>
endobj
47 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 22 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 24 0 R/Type/Page>>
endobj
14 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 26 0 R/Type/Page>>
endobj
105 0 obj
[109 0 R]
endobj
106 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2001; 28:2)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(372)Tj
ET
0 0 0 0 k
/GS0 gs
102.25 58.75 407.5 -10.83 re
f*
0.5 w
102.25 58.75 407.5 -10.83 re
S
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.1387 Tw 10 0 0 10 54 713.1616 Tm
[(inherited thrombophilic mutations. )17.7 (The presence of inher-)]TJ
0.07021 Tw 0 -1.2 TD
(ited thrombophilia may identify the subset of patients with)Tj
0.21049 Tw T*
(LAC and SLE at highest risk for thrombosis, and allow)Tj
0.0464 Tw T*
(anticipatory guidance or even prophylactic anticoagulation.)Tj
0.35741 Tw T*
(For patients who develop thrombosis, inherited throm-)Tj
-0.0127 Tw T*
(bophilia also may influence the therapeutic response to anti-)Tj
0 Tw T*
(coagulation.)Tj
/T1_2 1 Tf
0 -2.4 TD
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61 607.1616 Tm
[(1.)-875.1 (Petri M. Pathogenesis and treatment of the antiphospholipid)]TJ
1.675 -1.25 Td
[(antibody syndrome. Med Clin North )54.8 (Am 1997;81:151-77.)]TJ
-1.675 -1.25 Td
[(2.)-875.1 (De Stefano )17.7 (V)128.9 (, Finazzi G, Mannucci PM. Inherited thrombophilia:)]TJ
1.675 -1.25 Td
(Pathogenesis, clinical syndromes, and management. Blood)Tj
0 Tc 0 Tw 0 -1.25 TD
(1996;87:3531-44.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(3.)-875.1 (Gruppo R, Glueck CJ, )17.7 (W)79.9 (all E, Roy D, )17.7 (W)79.9 (ang P)110.7 (. Legg-Perthes)]TJ
1.675 -1.25 Td
(disease in three siblings, two heterozygous and one homozygous)Tj
T*
[(for the factor )17.7 (V)-257.2 (Leiden mutation. J Pediatr 1998;132:885-8.)]TJ
-1.675 -1.25 Td
[(4.)-875.1 (Balasa )17.7 (VV)128.8 (, Gruppo R, Glueck CJ, et al. )17.7 (The relationship of)]TJ
1.675 -1.25 Td
(mutations in the methylenetetrahydrofolate reductase, prothrombin,)Tj
T*
[(and plasminogen activator inhibitor)19.7 (-1 genes to plasma levels of)]TJ
T*
[(homocysteine, prothrombin, and plasminogen activator inhibitor)19.7 (-1)]TJ
T*
[(levels in children and adults. )17.7 (Thromb Haemostas 1999;81:739-44.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (Zimmerman SA, Howard )17.7 (T)79.9 (A, )17.7 (Whorton MR, Rosse )17.7 (WF)79.7 (, )17.7 (W)79.9 (are RE.)]TJ
1.675 -1.25 Td
[(Thrombophilic DNA)-220.2 (mutations as independent risk factors for)]TJ
T*
(stroke and avascular necrosis in sickle cell anemia. Hematology)Tj
T*
(2001; \(in press\).)Tj
-1.675 -1.25 Td
[(6.)-875.1 (Alarcon-Segovia D, Deleze M, Oria CV)128.8 (, et al. )54.8 (Antiphospholipid)]TJ
1.675 -1.25 Td
(antibodies and the antiphospholipid syndrome in systemic lupus)Tj
T*
[(erythematosus: )54.8 (A)-220.1 (prospective analysis of 500 consecutive patients.)]TJ
T*
(Medicine 1989;68:353-65.)Tj
31.325 38.421 Td
[(7.)-875.1 (Love PE, Santoro SA. )54.8 (Antiphospholipid antibodies: )54.8 (Anticardiolipin)]TJ
1.675 -1.25 Td
(and the lupus anticoagulant in systemic lupus erythematosus \(SLE\))Tj
T*
[(and in non-SLE disorders. )54.8 (Ann Intern Med 1990;1)36.8 (12:682-98.)]TJ
-1.675 -1.25 Td
[(8.)-875.1 (Berube C, Mitchell L, Silverman E, et al. )17.7 (The relationship of)]TJ
1.675 -1.25 Td
(antiphosphlipid antibodies to thromboembolic events in pediatric)Tj
T*
[(patients with systemic lupus erythematosus: )54.8 (A)-220.1 (cross-sectional study)64.8 (.)]TJ
T*
(Pediatr Res 1998;44:351-6. )Tj
-1.675 -1.25 Td
[(9.)-875.1 (Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ,)]TJ
1.675 -1.25 Td
[(Eisenber)17.7 (g PR, Miletich JP)110.7 (. Mutation in the gene coding for)]TJ
T*
[(coagulation factor )17.7 (V)-257.2 (and the risk of myocardial infarction, stroke,)]TJ
T*
(and venous thrombosis in apparently healthy men. N Engl J Med)Tj
0 Tc 0 Tw T*
(1995;332:912-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (Hagstrom JN, )17.7 (W)79.9 (alter J, Bluebond-Langner R, )54.8 (Amatniek JC, Manno)]TJ
2.175 -1.25 Td
[(CS, High KA. Prevalence of the factor )17.7 (V)-257.2 (Leiden mutation in)]TJ
T*
(children and neonates with thromboembolic disease. J Pediatr)Tj
0 Tc 0 Tw T*
(1998;133:777-81.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Nowak-Gottl U, Schneppenheim R, )17.7 (V)59.8 (ielhaber H. )54.8 (APC resistance in)]TJ
2.1381 -1.25 Td
(childhood thromboembolism: Diagnosis and clinical aspects. Semin)Tj
T*
(Thromb Hemostas 1997;23:253-8.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Fijnheer R, Horbach DA, Donders RCJM, et al. Factor )17.7 (V)-257.2 (Leiden,)]TJ
2.175 -1.25 Td
(antiphospholipid antibodies and thrombosis in systemic lupus)Tj
T*
[(erythematosus. )17.7 (Thromb Haemostas 1996;76:514-7.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (V)110.8 (andenbroucke JP)110.7 (, van der Meer FJM, Helmerhorst FM, Rosendaal)]TJ
2.175 -1.25 Td
[(FR. Factor )17.7 (V)-257.2 (Leiden: should we screen oral contraceptive users and)]TJ
T*
[(pregnant women. BMJ 1996;313:1)36.8 (127-30.)]TJ
-2.175 -1.25 Td
[(14.)-875.1 (W)79.9 (elch GN, Loscalzo J. Homocysteine and atherothrombosis. )]TJ
0 Tc 2.175 -1.25 Td
(N Engl J Med 1998;338:1042-50.)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
26 0 obj
<>stream
8;Z\7$a.Ai%*ST&R-RGL&B>5gUV'XVUf_E?FjtEF#h;9#V]]p*jY\I#bj8`HW_'a[_87;A./pe4!?H@F[\@d5:4o7EK.1TjH\kARB[.L#Sur
H70lPjje4@",=3!;O]#!0OZji0^JO>G;hsS#nPj^%kJ*"VX&:M=&SETI1jbZ^`D?6
Cdp*WP/ZgCimOMdL>@H-.<9^.@e,@jVKRi>o-;,rRblJbW7'
endstream
endobj
30 0 obj
[/Indexed/DeviceRGB 255 29 0 R]
endobj
29 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
50 0 obj
<>
endobj
53 0 obj
<>
endobj
61 0 obj
<>
endobj
88 0 obj
<>
endobj
100 0 obj
<>
endobj
62 0 obj
<>
endobj
78 0 obj
<>stream
HLS{PTUeոzRJM]FyC$m%7]h.X>,Qs&,ёb +۷3v9g99ߡ0)==srk9#aeLIa
QƄ+BXkjGAcQ#vʇ13R"ܩbLbBӡ &bQLs/:,N1͞
Ȓ7SSl61+T)fYi}T:EX$,fi3vGQiELyN4f9$ѪsqZfjq6CMS)jFQ¨j*NL'^ϰia[nh4
`N52$S^)4_yȪѩw0({
˭[&HZ&Vy(fN)(^RKpg:N8YOg&$77}^`1|#t2l,dw6o(\d4j\
Q 0]TRI8y,\e(0B3<^d]9V{|W]-
F2{1z\թp!"ĵ#%і}ғ]d͝U%-9yZUSO5$cMB;]ϔOF@_KxpNFB
g@B' (Sm
ZR2ܕeq/9H>>~
@`dQY.S\S>^a|>?X^UvhDxC Fe֭,f{ZB̤4l)}u)˂ǴwB$2PR{$iu^t^`{vغt+碌ILDA|b
܄IT!}XЎ0Y]Sa
cafw.UU-dvH<(3]2 ճ.Մs.v@"V\0Xqf~k-T+7;v1|{Ԃ^eG}!7qhv!Pw(Czo{։עqbW-(~S\@{nװFq õ
&\{bC)q?E]5řNTQ]%@C|Rz(( ʲ"s
̲̜XHJXl;|XFO.%k:ֽ/G tѺK'ik']q{}\BbjCE<